Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mefway (18F)
- Development stage
- Unknown
- Lead developer
- University of California, Irvine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
mefway (18F) (also known as mefWAY F18) is a fluorine-18 labeled radiopharmaceutical that acts as a highly selective antagonist for the serotonin 5-HT1A receptor. Developed as a positron emission tomography (PET) imaging tracer, it is designed to quantify 5-HT1A receptor distribution and density in the brain, which is implicated in various central nervous system disorders such as Alzheimer's disease, Parkinson's disease, major depressive disorder, and anxiety. Compared to carbon-11 labeled tracers like [11C]WAY-100635, mefway (18F) offers a longer half-life and greater resistance to in vivo defluorination, providing improved imaging quality and quantification capabilities.
- Other names
- 18F-mefway[18F]MeFWAYN-{2-[4-(2-methoxyphenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-[18F]-fluoromethylcyclohexane)carboxamidemefWAY F18mefway F18 injectiontrans-[18F]mefwaytrans-mefway (18F)trans-mefway F18
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on mefway (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mefway (18F).